AbbVie has halted enrollment in all ongoing studies of depatuxizumab mafodotin, after an Independent Data Monitoring Committee (IDMC) recommended a phase 3 study of the treatment be stopped due to a lack of survival benefit.
Highest incidence seen for patients with non-small cell lung cancer and triple-negative breast cancer
The use of postoperative stereotactic radiosurgery could be a substitute for whole-brain radiotherapy, which has been linked to cognitive adverse effects.
Over 10 000 brain and CNS tumors are diagnosed in adolescent and young adults each year.
Two years post-enrollment, 43% of patients in the combination therapy group were alive.
The adaptive trial design will allow GBM patients to benefit from precision medicine.
Researchers found that brain tumor mutations could be detected from ctDNA in cerebrospinal fluid.
A reduction primarily in grey matter and expansion of the brain’s ventricles was observed.
Researchers found a decrease in use of radiation treatment after 2005.
Survival rates were similar for both methods, but targeted radiation helped preserve cognition.